BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0

Historical Institutional Holders from Q3 2017 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Debt / NOTE 0.599% 8/0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Principal Value Change Price Investors
2024 Q3 $0 $0 -$502M 0
2024 Q2 $505M $502M +$56.3M $0.99 48
2024 Q1 $414M $407M +$17M $0.98 54
2023 Q4 $397M $393M +$28.8M $0.99 61
2023 Q3 $364M $359M -$20.2M $0.97 60
2023 Q2 $386M $380M -$16.9M $0.98 55
2023 Q1 $400M $416M +$50.3M $1.03 57
2022 Q4 $356M $378M +$28.1M $1.06 53
2022 Q3 $320M $318M -$57.3M $0.99 48
2022 Q2 $379M $375M -$6.31M $0.99 50
2022 Q1 $379M $378M +$23.6M $1.00 48
2021 Q4 $354M $371M -$45.7M $1.05 46
2021 Q3 $394M $405M -$3.32M $1.03 47
2021 Q2 $396M $413M -$70.4M $1.04 43
2021 Q1 $470M $481M +$19.4M $1.02 47
2020 Q4 $445M $479M +$16M $1.07 50
2020 Q3 $435M $456M +$2.09M $1.05 48
2020 Q2 $423M $523M +$5.04M $1.22 53
2020 Q1 $424M $444M +$57.3M $1.05 51
2019 Q4 $366M $389M -$116M $1.06 49
2019 Q3 $483M $477M -$7.28M $0.99 42
2019 Q2 $488M $509M +$21.7M $1.04 45
2019 Q1 $467M $480M -$21.8M $1.02 45
2018 Q4 $491M $490M +$16M $0.99 41
2018 Q3 $474M $504M +$63.2M $1.07 42
2018 Q2 $388M $395M +$22.3M $1.01 36
2018 Q1 $391M $370M -$27.1M $0.94 38
2017 Q4 $404M $404M +$2.27M $1.00 46
2017 Q3 $401M $407M +$407M $1.02 39